r/SRPT – Still Watching After 8 Months
Traders:
https://investorrelations.sarepta.com/node/25206/pdf
About 8 months ago, I exited my position in Sarepta Therapeutics (SRPT). At the time, the story was becoming too dependent on uncertainty around ELEVIDYS, regulatory pressure, and whether the company could actually transition into a sustainable commercial biotech business.
Since then, I’ve continued following the stock closely.
What’s interesting now is that the latest earnings may have changed the conversation a bit.
A few things stand out to me:
• SRPT is no longer just a “hope and pipeline” biotech.
The company generated meaningful revenue and positive EPS this quarter.
• The market narrative is evolving beyond only ELEVIDYS.
Now there’s increasing focus on the siRNA platform, FSHD, DM1, and broader long-term pipeline potential.
• The refinancing and runway situation also improved significantly.
The 2030 convertible notes removed near-term funding pressure, which matters a lot for biotech names.
At the same time, the risks are still very real:
• ELEVIDYS remains controversial.
• Black box liver warnings and safety concerns are serious.
• FDA restrictions for non-ambulatory patients are still a major overhang.
• This is still a high-volatility biotech stock.
What I find interesting is that despite all the negative headlines over the last several months, SRPT has continued operating, generating revenue, and expanding pipeline visibility.
So for now, I’m not posting this as a bullish call or financial advice.
I’m simply keeping SRPT on my watchlist and continuing to observe whether the company is truly transitioning from a speculative biotech story into a more established commercial biotech platform.
That distinction will probably determine where this stock trades over the next few years.
Curious to hear how others are viewing SRPT at this stage.